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The Road to Stockholm
In his Nobel Lecture lasr fall, Bruce Merrifield, John D. Rocke-
feller Jr. Professor of The Rockefeller University, quoted these
words written in 1906 by the great German chemist Emil
Fischer:
"Whereas cautious professional colleagues fear that a rational
study of this class of compounds, because of their complicated
structure and their highly inconvenient physical charaeteristcs,
would tOday still uncover insurmountable difficulties, other
optimistically endowed observers, among which I count myself,
are inclined to the view rhat an attempt should at least be made
to besiege this virgin fortress .... "
If Fischer's rhetoric sounded convoluted and old-fashioned,
particularly as spoken by a Texas-born American, his message
was visionary. The compounds he was referring ro were proteins,
and he knew rhat within their daunting complexities and
"inconvenient characteristics" lay the answers to some of the
most central questions in biology and medicine.
Fischer himself helped to open rhe path toward rhe "virgin
fortress." Others pushed farther along the trail. Then, in the
1960s, Bruce Merrifield veered off in a different direction and
came up with a simple, ingenious Strategy for storming the
citadel. He was awarded the 1984 Nobel Prize in Chemistry for
the development of "chemical synthesis on a solid matrix," a
totally novel technology that is helping scientists penetrate and
manipulate biological molecules with a precision Fischer could
only dream o( His work, stated the Royal Swedish Academy of
Sciences, "has created completely new possibilities in the field
of peptide and protein chemistry ... as well as in the field of
nucleic acid chemistry where other researchers have applied
Merrifield's ideas."
The news of the prize was greeted with particular pride on the
campus where the achievement honored had been born and
nurtured. Dr. Merrifield has been at Rockefeller since 1949, an
emblematic year in which, says his wife, Elizabeth, "he gOt his
Ph. D. from UCLA on a Sunday, we gOt married On Monday, and
we left for New York on Tuesday." The new celebrity - a quiet,
shirtsleeves man whose nonworking pleasures center on camp-
ing trips with his family and fiercely competitive Ping-Pong-
anticipated with some trepidation the trial by white tie and tails
awaiting him in Stockholm. In retrospect he confesses, "We had
a wonderful time."
Stockholm, December 10, 1984.
Bruce Merrifield greets his
family after the Nobel ceremony.
Dr. Merrifield in his Rockefeller
office. On the wall behind him,
a photograph of his mentor, the
late D. W Woolley.
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TINY PLASTIC BEADS
Living tissue is built primarily of proteins. The all-important
enzymes, tens of thousands in each cell mobilizing the chemical
reactions that fuel and sustain life, are proteins. Most of the
hormones that regulate these reacrions are proteins or peptides,
smaller versions of proteins. One way scientists study these
molecules is by isolating them from their natural habitat, nOt
always easy or practical to do since some are as rare or unstable as
they are crucial. Another way is by chemical synthesis: making
them in the laboratory.
Amino acids are the basic constituents of peptides and pro-
teins, which are huge polypeptides. With twenty different
amino acids, Nature effortlessly effects millions of combina-
tions, from tiny dipeptides - twO amino acids - to sinuous
proteins thousands of amino acids long. For the biochemist
seeking to emulate Nature the task is a little like playing three-
dimensional chess in the dark without a board.
The major problem lies in the formation of the bonds that
o~
°D
couple amino acids. Amino acids contain different reactive
chemical groups: an amino group, a carboxyl group, and often
another group on a side chain. In forming a peptide chain, these
groups must be chemically "protected," or blocked, against
unwanted combinations. To prepare a dipeptide, the amino
group of one unit and the carboxyl group of the other must be
blocked. The carboxyl group of the first can then be activated to
form a bond with the free amino group of the second. To add a
third unit, it is necessary to "deprotect" one of the blocked
groups in the dipeptide.
Emil Fischer was the first to synthesize dipeptides. His
student Max Bergmann, together with Leonidas Zervas, made
the key discovery (of the carbobenzoxy group that reversibly
blocks the amino group), which made the so-called classical
method of synthesis broadly available to peptide chemists.
Bergmann was also responsible for bringing peptide chemistry
to this country. He worked at Rockefeller from 1934 until his
death in 1944. (His old office is now Dr. Merrifield's.) Classical
methods were still in use when Dr. Merrifield began synthesiz-
ing peptides as a j}lnior member of the Rockefeller laboratory of
D. W. Woolley. "They were effective," he says, "but they were
laborious and time-consuming. Depending on the size and
complexity of the peptide, the process could take months or
even years. For a beginner like me it was extremely frustrating."
The coupling steps, carried out in solution, required that
each time a new amino acid was added to the growing chain the
products had to be removed from the reaction vessel and pu-
rified. However, when crystallization, the standard purification
procedure, was used with long chains, it frequently yielded
amorphous material contaminated with by-products, neces-
sitating further purification. "Plodding along," Bruce Mer-
rifield began to wonder whether there might be another way.
Then, in 1959, he got an idea.
Dr. Merrifield likens the amino acids in a peptide to the
boxcars of a train. The idea that came to him was to put the train
on a track. "My thought," he says, "was to assemble peptide
chains by attaching the amino acids to one another on a solid
suPPOrt. The first amino acid would be attached to the support
by one end, leaving only the desired end receptive to the next
amino acid. Since the growing chain was anchored within the












FAR RIGHT. William Heath,
left, andJames Tam at an
apparatus in which a hydrogen
fluoride mixture deprotects and
cleaves peptides. With Dr.
Merrifield they designed major
improvements in the chemistry of
the process, resulting in purer
synthetic products. Dr. Tam, a
member of the laboratory since
1976, is studying a tumor
growth factor and cancer genes
and is working to develop a
synthetic malaria vaccine.
The first automatic peptide
synthesizer. The synthetic
chemistry takes place in the
right-hand cabinet. The
programmer is on the left side.
matrix of the insoluble support, the peptide would also be
insoluble. After each synthetic reaction, the mixture could be
• filtered and washed to remove excess reactants and by-products
without having to be removed from the reaction vessel. The
growing chain could be purified step-by-step by a simple, rapid
procedure rather than by tedious crystallization." With a nod
from Dr. Woolley, he began looking for the track.
"I originally had cellulose in mind because it had been useful
for chromatography of proteins," he explains. "But cellulose is
unstable with some reagents, and when I used it everything
turned to goo. So, then, I decided to try plastics. I really didn't
know much about polymer chemistry at the rime and I sweated
through several dead-end attempts before I got to polystyrene. I
did know I would have to modify the material - put a reacting
group on it - because otherwise it would be inert. Well, there
are a lot of ways to activate polystyrene and I managed to pick all
the wrong ones before I finally found a reaction that worked."
The beads of polystyrene resin Dr. Merrifield used are two-
thousandths of an inch in diameter, gigantic compared to
peptides. And they blow up like balloons when immersed in
solvent. Each bead potentially can support a trillion peptide
chains. The "track" is in fact a porous gel, a mesh structure that
allows penetration of reagents as it swells. Once the peptide is
synthesized, it can be removed from the suppOrt.
Proving his concept feasible, which he had thought would
take about three months, tOok three years. "During all that
time, I produced no publications and it didn't appear I was
making progress. In some other places," he reflects, "I think
there would have been raised eyebrows."
In allowing his young colleague to continue working unham-
pered on an unconventional idea he thought had merit, Wayne
Woolley followed an institutional precedent which, by and
large, has given considerable leeway to talented researchers.
Woolley himself tended to wander wherever his interests led
him. In a series of brilliant studies, he helped to clarify the
function of vitamins, particularly the B vitamins, and of anti-
metabolites that interfere with vitamin activity, and to establish
the cause and treatment of pellagra. From nutritional concerns,
he turned to the role of the hormone seroronin in hypertension,
and from there to a recognition of the influence of serotOnin on
mental processes. His book, The Biochemical Bases of Psychoses,
published in 1962, presaged what was to become one of the
most fertile fields in contemporary science.
Woolley, whom Dr. Merrifield remembers as "the brightest
man I ever knew," was blind through most of his working life,
the result of diabet-es. He died from the effects of the disease in
1966 at the age of fifty-two. "He lost his sight shortly after he
came here," Dr. Merrifield says. "However, Herbert Gasser,
then the director of Rockefeller, recognizing Woolley's gifts, set
him up in a lab and let him work."
THE MERRIFIELD MACHINE AND
THE ROCKEFELLER ENZYME
Dr. Merrifield's first modest success with the method that came
to be known as solid-phase peptide synthesis was a tetrapeptide:
a simple chain of four amino acids. (The classical method is now
called solution-phase synthesis.) After working Out some bugs
in the chemistry, he attempted to grow a real-life compound,
bradykinin, a nine amino-acid hypotensive hormone. He com-
pleted its synthesis in less than a week. John Stewart, another
member of Woolley's group, who had spent a year synthesizing
three analogs of bradykinin by solution-phase, applied solid-
phase and prepared nearly fifty analogs during the following
year. Not long after, Garland Marshall, Dr. Merrifields first
graduate student, synthesized angiotensin, a polypeptide hor-
mone that raises blood pressure. "I had no idea how long a
peptide we could make," Dr. Merrifield says. "We just kept
inching up."
From the beginning, he had been thinking about the pos-
sibility of auromating his process. "I even tried to set up a
simple apparatus myself," he says, "but I couldn't get it to
work. After bradykinin, John Stewart offered to help. He was a
radio buff, so he handled the wiring while I took care of the
plumbing. The valves were machined by Nils Jernberg, the
University's instrument maker. John and I constructed the
synthesizer at night in the basement at home."
In 1965, they completed a working model of an automatic
peptide-making machine. When Dr. Merrifield and a student,
Arnold Marglin, applied it to the synthesis of insulin, the
smallest polypeptide that qualifies as a protein, they obtained
results in a fraction of the time previously required with classical
methodology.
The challenge still looming was an enzyme. The one Dr.
Merrifield selected, for scientific and sentimental reasons, was
ribonuclease A, which catalyzes the breakdown of ribonucleic
acid (RNA). He chose it because it is one of the smallest
enzymes - 124 amino acids long - and its properties were
well known, mostly because of research done at Rockefeller. It
had been isolated and named by Rene Dubos and crystallized by
Moses Kunitz. Its molecular weight had been determined by
Alexandre Rothen and its chemical struCture mapped in the
laboratory of Stanford Moore and William Stein, both of whom
began at Rockefeller under Max Bergmann and went on to share
a Nobel Prize in Chemistry in 1972.
Three hundred and sixty-nine chemical reactions and eleven
thousand nine hundred and thirty-one mechanical steps later,
Bernd Gune (now of the University of Zurich) and Dr. Mer-
rifield had a chain. However, biologically born enzymes twist
and bend, and their shapes are critical to their function. It had
been discovered a few years earlier in Christian B. Anfinsen's
laboratory at the National Institutes of Health that when natu-
ral ribonuclease A is unfolded, thereby losing its three dimen-
sional structure and enzymatic activity, it refolds by itself and
regains activity if allowed to stand in solution. The question
was, Would the synthetic enzyme also fold spontaneously into
the natural structure? The answer was yes. However, it had
chemical impurities.
"The goal in synthesis," Dr. Merrifield explains, "is to come
as close as possible to a one-hundred percent yield. That is, each
time a new amino acid is added the coupling should be com-
plete. But if, for example, the second amino acid couples with
only ninety-eight percent of the first, the third will react not
only with the dipeptide but also with the unreacted two percent
of the first amino acid, to produce a contaminating by-product.
Even with the slightest deviations the accumulation in a long
chain can add up considerably, and some of our early products
were pretty crude. Although we had succeeded in making an
enzyme with eighty percent ofexpected ribonuclease activity-
and I was convinced the yields could be improved - a lot of
people were skeptical." (One distinguished peptide chemist,
Dr. Merrifield remembers, assessed solid-phase as "amusing.")
For the past twenty years Dr. Merrifield has dedicated a major
part of rhe effort in his laboratory to confirming his conviction,
refining rhe chemisrry and developing new suppOrt marerials,
rackling ever more difficult syntheric challenges and higher
molecular numbers. "We're at the point," he says, "where we
can make almost any peptide we want with a good level of
purity." Among the compounds his group has synthesized are
the hormones glucagon, important in blood sugar regulation,
and thymosin, involved in white blood cell development, and a
variety of growth factOrs, antibiotics, and tOxins. Anaphy-
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FAR LEFT. In a return to
ribonucLease, first synthesized in
1969, Nagarajan
Chandramouli operates a
manual synthesizer to make the
enzyme with modified activity.
With him, research assistant
Guadalupe Gautier.
CENTER. David Andreu, left,
acquaints visiting scientist Li,
Zong-qu from the People's
Republic of China with the
operation ofa computerized
synthesizer. Dr. Andreu is
making a polypeptide similar to
glucagon, which will block
receptor sites for the hormone in
the liver.
NEAR LEFT. Bruce Erickson
with a model ofbetabe/lin, a 65
amino-acid protein he created to
show that folding patterns mu/d
be predicted, a first step toward




electron micrograph of cross-
linked polystyrene beads used in
solid-phase peptide synthesis.
Center. Autoradiograph of a




After synthesizing the whole
ribonuclease molecule, Dr.
Merrifield's laboratory went on
to study the enzyme by
synthesizing the peptides at each
end. The carboxyl end is shown
in light orange, the amino end
in gray. The dark orange areas
represent catalytic sites.
latoxins, a group of inflammation mediators, have been a special
interest of lab member Bruce Erickson, who is seeking to design
anti-inflammatory drugs for use in such conditions as rheu-
matoid arthritis.
One current projeer is the synthesis of interferon, a protein of
one hundred sixty-six amino acids, which is produced by the
body to fight viral infection and may have anti-cancer proper-
ties. The work is being conduered by a former student of Dr.
Merrifield's from his days as a lab instructor at UCLA, who
interrupted her studies to marry the teacher and rear five
daughters and a son. Mrs. Merrifield resumed her scientific
career five years ago. ''I'm at the hard part now," she says,
"purifying the molecule and getting it to fold right."
Dr. Merrifield has had a number of apt students. George
Barany, sixteen years old and fresh out of high school when he
was accepted as a Ph. D. candidate at Rockefeller, has devoted
considerable attention to methods for making difficult sulfur-
containing compounds. Now leading his own group at the
University of Minnesota, Dr. Barany is continuing to develop
new solid-phase chemistry. Last December he was included in a
selection by Science Digest of the country's brightest scientists
under forty.
WHY MAKE PEPTIDES?
For basic researchers, the reason for synthesizing molecules is
the hope of understanding biology better. "Sometimes," says
Dr. Merrifield, "you come upon a new entity. You want to find
out what it is, what its properties are." Until recently, bio-
chemists had known of a number of important peptide hor-
mones, but, in general, they had assumed peptides to be
relatively minor players on the biochemical stage. They found
out they were wrong. One of the exciting events in the past
decade was the discovery that neuropeptides, hormones in the
brain, bear major responsibility for mediating activity in the
nervous system. Much of the pioneer research on these com-
pounds depended on solid-phase synthesis.
Peptides and proteins also serve as growth factors, a major
areaunder study for some time by James Tam and more recently
by graduate fellow William Heath. During his first couple of
years in the lab, Bill Heath worked with Dr. Merrifield and Dr.
Tam on ways to eliminate unwanted synthetic side reaerions.
"Now," he says, ''I'm using the improvements we made to put
together epidermal growth faeror. It's a complicated struerure,
at least half the amino acids in it are considered problems, so it
really tests the methodology to the utmost. That makes it
interesting technically, but this particular peptide is also excit-
ing because part of its receptOr molecule is an oncogene - a
cancer gene."
For thirty years, Dr. Merrifield has lived in the suburban
town of Cresskill, New Jersey, and for all those years he has
driven to work with a neighbor and Rockefeller colleague,
Vincent Allfrey. "Bruce drives and I read," says Dr. All frey.
"We've gone through four volumes of Churchill's memoirs and
all the Lewis and Clark journals - and a number of cars." They
also talk shop. Dr. Allfrey studies proteins in the nucleus of cells
that affect the activity of DNA. "Bruce and I have collaborated
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on a number of projects. For example, his people and mine have
been creating peptides to help us ask about how enzymes work
in the nucleus and how certain proteins are programmed to get
in and Out of there. All kinds of interesting questions."
Another reason for making biological molecules is medical
application. In 1966 Emil Kaiser was working at Armour
Pharmaceuticals in Chicago. "Armour had wanted to make
peptide drugs for a long time," he says, "but we had been
discouraged by the difficulties and the cost of solution-phase."
After conferring with Dr. Merrifield at a scientific meeting, he
became a "true believer." A small solid-phase trial was set up at
Armour. Within a few years the group had successfully synthe-
sized several medically important compounds, including cal-
citonin, a thirty-two amino acid hormone effective in treating
Paget's disease and other bone conditions. "Today," says Dr.
Kaiser, "calcitonin is a multimillion dollar product."
Dr. Kaiser left Armour in 1982, ar rhe age of80, to come East
with his son, E. Thomas Kaiser, also a biochemist, who had
been invited to establish a group at Rockefeller. During a
reception in Dr. Merrifield's laboratOry to welcome the new-
comers, the senior Dr. Kaiser was offered a place in the lab to do
research on deprotecting methods. "So thanks to the party," he
says, "I didn't have to retire after all."
Since the days of ribonuclease synthesis, molecular biologists
have learned to make proteins by means of genetic engineering;
splicing out the genes that code for their natural manufacture
and using recombinant DNA techniques to clone copies of
them. This temarkable technology has thus made many large
proteins readily available. DNA, the genetic material, and
RNA, which transcribes and transmits its message, are nucleic
acids. In studying nucleic acids, researchers also have eagerly
incorporated solid-phase chemistry, adapting the principle
originally designed for peptides to string together the nu-
cleotide units of nucleic acids. Initially trained as a nucleic acid
chemist, Dr. Merrifield had himself anticipated the valuable
potential of this application and worked on the initial phases of
its development.
In research on smaller peptides, solid-phase synthesis re-
mains the most efficient methodology. Another very important
advantage of the technique is that it can be manipulated to effect
structural and functional modifications in molecules. "Most of
the people who use our method," Dr. Merrifield explains, "are
trying to make compounds with some special quality. They
want to make derivatives in which they have added or omitted
something, or made something more active, more specific, or
longer lived. A good example is the work on vasopressin by
Maurice Manning, who used to be with Dr. Woolley and is now
at the Medical College ofOhio. Among vasopressins properties,
it's an anti-diuretic, but it also raises blood pressure. Dr. Man-
ning has made hundreds of variants. He's now come up with an
analog that has good anti-diuretic properties but no adverse
blood pressure effects. He's also made an anti-anti-diuretic. The
first compound is for people who can't retain fluid, a terrible
problem in diabetes insipidus, and the second for people who
tetain too much.
"Name almost any peptide hormone and you'll find someone
has been working with it in this way. Another area generating a
good deal of interest is the possibility of making synthetic
peptide vaccines modified to eliminate the danger of inadver-
tent infection that exists with vaccines made from the killed or
attenuated infectious organisms themselves."
The sleek, computerized solid-phase synthesizers in use to-
day are manufactured commercially. Dr. Merrifield's original'
Model T, exhibited for a number of years in a small museum of
historic scientific instruments at Rockefeller, is currently being
readied for inclusion in the permanent collection of the
Smithsonian Institution in Washington, D.C. Meanwhile, its
inventor has demonstrated his fitness for future challenges.
In addition to delivering learned lectures and attending state
functions, Nobel Prize winners have the special honor of being
inducted into The Order of the Perpetually Leaping and Smiling
Frogs during the Santa Lucia Ball at the University of Stock-
holm. As part of the initiation the inductees are ordered,
appropriately, to leap like frogs. "One of my kids gOt a picture of
me," says Bruce Merrifield. "My glasses are flying and my feet
are d,,, off ,h, gmund. " ~
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